The estimated Net Worth of Emily Luisa Hill is at least 6.73 百万$ dollars as of 16 August 2024. Ms. Hill owns over 8,938 units of PTC Therapeutics Inc stock worth over 3,261,109$ and over the last 5 years she sold PTCT stock worth over 1,135,301$. In addition, she makes 2,336,650$ as Principal Financial Officer、 Treasurer at PTC Therapeutics Inc.
Sign up
Ms. Hill PTCT stock SEC Form 4 insiders trading
Emily has made over 18 trades of the PTC Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 8,938 units of PTCT stock worth 90,989$ on 16 August 2024.
The largest trade she's ever made was exercising 26,033 units of PTC Therapeutics Inc stock on 8 January 2021 worth over 613,337$. On average, Emily trades about 2,452 units every 70 days since 2019. As of 16 August 2024 she still owns at least 101,057 units of PTC Therapeutics Inc stock.
You can see the complete history of Ms. Hill stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Emily Hill biography
Emily Luisa Hill serves as Principal Financial Officer, Treasurer of the Company. Ms. Hill joined the Company in November 2013 as Executive Director, Investor Relations, became Vice President Investor Relations in January 2018 and Senior Vice President, Head of Investor Relations in January 2019. She also serves as a director of a subsidiary of PTC. Prior to joining the Company, Ms. Hill was Director of Investor Relations at Warner Chilcott from 2011 to 2012. From 2008 to 2010, Ms. Hill was Senior Manager of Investor Relations at Genzyme Corporation. From 2007 to 2008, Ms. Hill was a Biotech Equity Research Associate at Summer Street Partners. Ms. Hill has a BA from Hamilton College, an MS in pharmacology from Tufts University School of Biomedical Research and received her MBA from Fordham University.
What is the salary of Emily Hill?
As the Principal Financial Officer、 Treasurer of PTC Therapeutics Inc, the total compensation of Emily Hill at PTC Therapeutics Inc is 2,336,650$. There are 3 executives at PTC Therapeutics Inc getting paid more, with Stuart Peltz having the highest compensation of 7,759,440$.
How old is Emily Hill?
Emily Hill is 40, she's been the Principal Financial Officer、 Treasurer of PTC Therapeutics Inc since 2019. There are 19 older and no younger executives at PTC Therapeutics Inc. The oldest executive at PTC Therapeutics Inc is Dr. Allan Steven Jacobson, 75, who is the Independent Co-Founder, Chairman of Scientific Advisory Board & Director.
What's Emily Hill's mailing address?
Emily's mailing address filed with the SEC is C/O REPLIMUNE GROUP, INC., 500 UNICORN PARK DRIVE, SUITE 303, WOBURN, MA, 01801.
Insiders trading at PTC Therapeutics Inc
Over the last 12 years, insiders at PTC Therapeutics Inc have traded over 50,602,930$ worth of PTC Therapeutics Inc stock and bought 3,730,934 units worth 57,374,337$ . The most active insiders traders include Suisse/ Credit、Adam Koppel、Bioventures Cayman Ltd Hbm. On average, PTC Therapeutics Inc executives and independent directors trade stock every 16 days with the average trade being worth of 888,748$. The most recent stock trade was executed by Pierre Gravier on 16 July 2024, trading 2,269 units of PTCT stock currently worth 77,191$.
What does PTC Therapeutics Inc do?
ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
What does PTC Therapeutics Inc's logo look like?
Complete history of Ms. Hill stock trades at PTC Therapeutics Inc、Replimune Inc
PTC Therapeutics Inc executives and stock owners
PTC Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Stuart Peltz,
Chief Executive Officer, Director -
Neil Almstead,
Chief Technical Operations Officer -
Mark Boulding,
Executive Vice President, Chief Legal Officer -
Emily Hill,
Principal Financial Officer, Treasurer -
Dr. Stuart W. Peltz,
Co-Founder, CEO & Exec. Director -
Christine Utter,
Senior Vice President - Finance, Chief Accounting Officer -
Mark Elliott Boulding,
Exec. VP & Chief Legal Officer -
Dr. Neil Almstead,
Chief Technical Operations Officer -
Michael Schmertzler,
Independent Chairman of the Board -
Allan Jacobson,
Independent Director -
Emma Reeve,
Independent Director -
David Southwell,
Independent Director -
Dawn Svoronos,
Independent Director -
Glenn Steele,
Independent Director -
Jerome Zeldis,
Independent Director -
Stephanie Okey,
Independent Director -
Dr. Allan Steven Jacobson,
Independent Co-Founder, Chairman of Scientific Advisory Board & Director -
Eric Pauwels,
Chief Business Officer -
Matthew Klein,
Chief Development Officer -
Jane Baj,
VP of Corp. Communications -
Alex Kane,
Investor Relations Officer -
Ellen Welch Ph.D.,
Chief Scientific Officer -
Christine Utter,
Sr. VP, Chief Accounting Officer & Head of People Services -
Adam Koppel,
Director -
Cameron Geoffrey Mc Donough,
Director -
Tuyen Ong,
Chief Medical Officer -
Marcio Souza,
Chief Operating Officer -
Pharma Holdings Ii, Llc Com...,
10% owner -
Mark Rothera,
Chief Commercial Officer -
Ronald C Jr Renaud,
Director -
Suisse/ Credit,
-
Claudia De Oliveira Ribeiro...,
President -
Bioventures Cayman Ltd Hbm,
10% owner -
Robert J. Spiegel,
Chief Medical Officer -
Richard Aldrich,
Director -
Ventures Inc.Vulcan Capital...,
-
Shane William Charles Kovacs,
EVP, CFO & Head of Corp Dev -
Axel Bolte,
Director -
Michael L Kranda,
Director -
Pierre Gravier,
CHIEF FINANCIAL OFFICER -
Mary L. Smith,
-
William F. Jr. Bell,
-
Alethia Young,
-
Lee Scott Golden,
EVP & CHIEF MEDICAL OFFICER